Afrezza’s Underperformance Is a Cause of Concern for MannKind Corporation (MNKD)

Share on FacebookTweet about this on TwitterShare on Google+Share on RedditShare on LinkedInPrint this pageEmail this to someone

Mannkind Corporation (NASDAQ:MNKD) is worried with respect to the performance of its inhaled insulin drug, Afrezza. The company’s drug is struggling to create a favorable impact in the diabetes market even after launching the product five months back. The company appeared to have done well in partnering with Sanofi SA (ADR) (NYSE:SNY) though it failed to translate into results. As a result, it is struggling  to find out the reasons why.

Nothing New

It appears that the Inhaled insulin drug’s struggle in the diabetes market is nothing new. That is because even Pfizer Inc. (NYSE:PFE) seemed to have met with the same fate when it launched the product, Exubera, sometime in 2006. However, the biggest worry for Mannkind Corporation (NASDAQ:MNKD) is that Afrezza is underperforming even in comparison with the Exubera, which is considered a failure commercially. As a result, Pfizer was forced to dump the product after one year’s time.

Mannkind Corporation (NASDAQ:MNKD) is unable to accept the underperformance of its drug in comparison with Exubera. The company believes that Afrezza is much superior in every respect compared to Pfizer’s Exubera. Therefore, the developer of the drug expects the drug to succeed where Exubera struggled to find success. However, following the launch of its product nearly five months ago, the company has remained empty hand unable to digest the underperformance.

Poor Marketing

Despite Mannkind Corporation (NASDAQ:MNKD)’s positive opinion about Afrezza, its failure could suggest that Sanofi SA (ADR) (NYSE:SNY) has probably failed to have learned lessons from Pfizer Inc. (NYSE:PFE)’s experience. That might have landed it in marketing the inhaled insulin drug poorly in the diabetes market.

While GlaxoSmithKline plc (ADR) (NYSE:GSK) has been successful in marketing the prescription drug of Tanzeum, a GLP-1 injection. Though the drug is not insulin, its comparison could suggest that Sanofi has failed to market the inhaled insulin drug effectively. Its years of experience in marketing also failed to help the Afrezza succeed.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

  • jackjack

    And did you bother to compare the marketing for Exubera and Afrezza? Exubera was heavily marketed ($370mil) and Afrezza has yet to be marketed ($0).

    That and the fact that Sanofi was partnered with Pfizer to bring Exubera to market but sold their share to Pfizer prior to launching the product.

    It would appear that Sanofi played their part in Exubera perfectly and is doing the exact opposite of what Pfizer did with Exubera. Hence they learned and are doing what they feel is best to bring Afrezza to market.

    They started by educating a handful of highly respected endos and now that Afrezza has been found to be extremely effective, better than anything currently on the market, they are moving to phase 2; a DTC marketing campaign.

    I hope you do a follow up in 2 months time.

    It may be best if you do some semblance of research before writing nonsense.

    • Bobby

      Looks like his research consists of reading AF.

  • O AJ

    Research and stop the plagiarism is all I can say. How did you get a forum to peddle this garbage. Be a leader not a lackey and do your own due diligence.

  • SarahKnows

    Do the world a favor and write something truthful and meaningful. Stop shilling for hedge funds. You’d have more class if you sold pencils on a street corner. This is total hogwash and you know it.

More in MNKD
Mankind Corporation (NASDAQ:MNKD), NASDAQ:MNKD
Mannkind Corporation (MNKD): Hedge Fund Now Believes It is a Zero — Too Harsh?

Tourbillon Capital Partners LP recently made the bold statement that Mannkind Corporation (NASDAQ:MNKD) would soon reach a level of worthlessness....

Close